RxDoctor Payments Data

Norman Numerof, MD

Internal Medicine · Avon, CONPI 1720192776

Payments from drug & device makers

$416in general payments, 2019–2025

Across 18 payments — averaging $23.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$132
  • Amgen$70
  • Johnson & Johnson$29
  • Lucid Diagnostics Inc.$23
  • AbbVie$20
  • Itamar Medical Inc$20
  • plus $123 from 8 others

What the payments were for

  • Food & beverage$416100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$416 in reported general payments places this provider in the 75th percentile of 1,430 internal medicine providers in Colorado.

See all internal medicine providers in Colorado

Medicare billing

Part B allowed, 2024
$96,886
Medicare patients
90
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban24$25,490
JardianceEmpagliflozin22$21,957
EliquisApixaban22$21,095
FarxigaDapagliflozin Propanediol13$19,983
RybelsusSemaglutide15$18,707
EntrestoSacubitril/Valsartan13$8,801
Incruse ElliptaUmeclidinium Bromide17$5,918
SynthroidLevothyroxine Sodium43$5,414
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,445
Pulmicort FlexhalerBudesonide11$2,961
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$2,471
Atorvastatin Calcium156$1,467
Tamsulosin Hcl42$1,038
Lisinopril115$887
Metoprolol Succinate60$877

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$25,49024 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$18$22,94424 claims
PfizerEliquis$12$21,09522 claims
AbbVieSynthroid$20$5,41443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,430 internal medicine providers in Colorado.

Other internal medicine in Avon

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →